ClinicalTrials.gg
CompletedNCT04560738Updated Nov 29, 2021

A Study to Evaluate the Metabolism and Excretion of [14C]-CC-92480 in Healthy Male Participants

A Phase 1 interventional study of [14C]-CC-92480 in Healthy Volunteers, sponsored by Celgene. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-11-29.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was May 2021, 5 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

This is a single-center, open-label study to be conducted in healthy adult male participants. This study is designed to characterize the biotransformation and excretion of [14C]-CC-92480 and to evaluate the safety and tolerability of [14C]-CC-92480 following a single oral dose of [14C]-CC-92480.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Healthy Volunteers
  • CC-92480
  • Healthy male
03

In context

Lead sponsor

Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.

Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.

First submitted after Celgene became part of Bristol-Myers Squibb.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must satisfy the following criteria to be enrolled in the study:

  1. Participant is ≥ 18 and ≤ 55 years of age at the time of signing the form (ICF).
  2. Participant is male.
  3. Participant must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted.
  4. Participant is willing and able to adhere to the study visit schedule and other protocol requirements.
  5. Participant is in good health, as determined by the Investigator at the time of signing the ICF.
  6. Participant agrees to abide by the requirements and restrictions outlined in the CC-92480 Pregnancy Prevention Plan for Participants in Clinical Trials.
  7. Participant must practice true abstinence or agree to use a barrier method of (condoms not made out of natural [animal] membrane [latex condoms are recommended]) during sexual contact with a pregnant female or a FCBP while participating in the study and for at least 90 days following administration of CC-92480, even if he has undergone a successful vasectomy. A FCBP is a female who: 1) has achieved menarche at some point; 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally (amenorrhea following cancer therapy does not rule out ) for at least 24 consecutive months (ie, has had menses at any time in the preceding 24 consecutive months).
  8. Participant has a (BMI) ≥ 18 and ≤ 33 kg/m2 at the time of signing the ICF.
  9. Participant has clinical laboratory safety test results, including (ALT)/aspartate aminotransferase (AST) results, that are within normal limits or considered not by the Investigator.

    1. count and absolute lymphocyte count (ALC) must be above the lower limit of normal at screening.
    2. (ANC) must be greater than 2500/microliter.
  10. Participant is afebrile, with supine systolic BP ≥ 90 and ≤ 140 mm Hg, supine diastolic BP ≥ 50 and ≤ 90 mm Hg, and pulse rate ≥ 40 and ≤ 110 bpm at screening.
  11. Participant has a normal or clinically acceptable 12-lead , with a corrected for heart rate using Fridericia's formula (QTcF) value ≤ 430 msec, at screening.

Exclusion criteria

Exclusion Criteria:

The presence of any of the following will exclude a participant from enrollment:

  1. Participant has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the participant from participating in the study.
  2. Participant has a history of chronic pruritus or chronic dermatologic disorder.
  3. Participant has or intolerance to first-generation antihistamine medications.
  4. Participant has a history of benign ethnic neutropenia.
  5. Participant has a history of any clinically significant and relevant neurological, gastrointestinal, renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine, hematological, allergic disease, drug allergies, or other major disorders as determined by the Investigator.
  6. Participant has any condition, including the presence of laboratory abnormalities, which places the participant at unacceptable risk if he were to participate in the study.
  7. Participant has any condition that confounds the ability to interpret data from the study.
  8. Participant was exposed to an drug (new chemical entity) within 30 days prior to dosing or 5 half-lives of that investigational drug, if known (whichever is longer).
  9. Participant has used any prescribed systemic or topical medication (including but not limited to analgesics, anesthetics, etc) within 14 days or 5 half-lives of that medication, whichever is longer, prior to dosing.
  10. Participant has used any non-prescribed systemic or topical medication (including vitamin/mineral supplements and herbal medicines) within 7 days prior to dosing.
  11. Participant has used inducers and/or inhibitors (including St. John's Wort) within 30 days prior to dosing. The Indiana University "Cytochrome P450 Drug Interaction Table" should be utilized to determine inducers and/or inhibitors of CYP3A (http://medicine.iupui.edu/clinpharm/ddis/table.aspx).
  12. Participant has any surgical or medical conditions possibly affecting drug absorption, distribution, metabolism, and excretion, eg, bariatric procedure.

    Note: prior appendectomy is acceptable, but prior cholecystectomy would result in exclusion from the study.

  13. Participant donated blood or plasma within 8 weeks prior to dosing to a blood bank or blood donation center.
  14. Participant has a history of drug abuse (as defined by the current version of the Diagnostic and Statistical Manual [DSM]) within 2 years prior to dosing, or positive drug test reflecting consumption of illicit drugs.
  15. Participant has a history of alcohol abuse (as defined by the current version of the DSM) within 2 years prior to dosing, or positive alcohol test.
  16. Participant is known to have serum hepatitis or known to be a carrier of surface antigen (HBsAg) or antibody (HCV Ab), or have a reactive result to the test for (HIV) antibodies at screening.
  17. Participant has a history of smoking/use of tobacco or nicotine-containing products within 3 months prior to check-in (Day -1).
  18. Participant has received immunization with a live or within 2 months prior to dosing or is planning to receive immunization with a live or live-attenuated vaccine for 2 months following dosing.
  19. Participant participated in a radiolabeled drug study, where exposures are known to the Investigator, within the previous 4 months prior to check-in (Day -1); or participated in a radiolabeled drug study, where exposures are not known to the Investigator, within the previous 6 months prior to check-in (Day -1). The total 12-month exposure from this study and a maximum of 2 other previous studies within 4 to 12 months of this study will be within the CFR-recommended levels considered safe: less than 5000 mrem whole body annual exposure, with consideration given to the half-lives of the previous radiolabeled study drugs received.
  20. Participant was exposed to significant radiation (eg, serial X-ray or computed tomography scans, barium meal, current employment in a job requiring radiation exposure monitoring) within 12 months prior to check-in (Day -1).
  21. History of less than 1 to 2 bowel movements per day.
  22. Participant is part of the study site personnel or a family member of the study site staff.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Administration of [14C]-CC-92480

    \[14C\]-CC-92480 will be administered as an oral solution. A single oral dose of \[14C\]-CC-92480, containing approximately 2 μCi of radioactivity, will be administered on Day 1 under fasted conditions.

    Drug: [14C]-CC-92480

Interventions

06

What researchers measure

Primary outcomes

  1. Cumulative excretion of [14C]-RA

    The total recovery of radioactivity (RA) will be computed as the sum of the cumulative excretion (as % dose) in urine and feces (and vomit, if applicable).

    Time frame: Up to approximately 15 days

  2. Pharmacokinetics -Tmax of total radioactivity, CC-92480 and its metabolites

    Time to reach maximum total radioactivity or concentration of CC-92480 and its metabolites

    Time frame: Up to approximately 15 days

  3. Pharmacokinetics - Cmax of total radioactivity, CC-92480 and its metabolites

    Maximum total radioactivity or concentration of CC-92480 and its metabolites

    Time frame: Up to approximately 15 days

  4. Pharmacokinetics - AUC0-t of total radioactivity, CC-92480 and its metabolites

    Area under the concentration-time curve from time zero to the last measured time point

    Time frame: Up to approximately 15 days

  5. AUC0-inf of total radioactivity, CC-92480 and its metabolites

    Area under the concentration-time curve from time zero extrapolated to infinite time

    Time frame: Up to approximately 15 days

  6. Pharmacokinetics - CL/F of total radioactivity, CC-92480 and its metabolites

    Apparent oral clearance

    Time frame: Up to approximately 15 days

  7. Pharmacokinetics - Vz/F of total radioactivity, CC-92480 and its metabolites

    Apparent volume of distribution

    Time frame: Up to approximately 15 days

  8. Pharmacokinetics - t1/2 of total radioactivity, CC-92480 and its metabolites

    Terminal elimination half-life

    Time frame: Up to approximately 15 days

  9. Metabolic profiling in urines and feces

    The percentage of the administered dose attributed to CC-92480 and its metabolites in urine and feces

    Time frame: Up to approximately 15 days

Secondary outcomes

  1. Adverse Events (AEs)

    An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE.

    Time frame: From enrollment until at least 28 days after completion of study treatment

07

Study locations

1 site
  • Covance Clinical Research Unit Inc
    Madison, Wisconsin 53704, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2020 to primary completion in May 2021, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2020
First posted
Sep 23, 2020
StartActual
Oct 15, 2020
Primary completionActual
May 13, 2021
CompletionActual
May 13, 2021
Last update
Nov 29, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04560738
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Sep 23, 2020
Start date
Oct 15, 2020
Primary completion
May 13, 2021
Completion
May 13, 2021
Last update
Nov 29, 2021

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mezigdomide

Start the discussion